Hydrocortisone MR is under clinical development by Diurnal Group and currently in Phase III for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According to GlobalData, Phase III drugs for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Hydrocortisone MR LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hydrocortisone MR overview
Hydrocortisone (Efmody) is a synthetic corticosteroid, acts as an anti-inflammatory agent. It is formulated as modified release hard gelatin capsules for oral route of administration. Efmody is indicated in adult and adolescents of 12 years and over for the treatment of congenital adrenal hyperplasia.
Hydrocortisone MR (Chronocort) is under development for the treatment of Addison's disease and congenital adrenal hyperplasia. The drug candidate is administered orally. Chronocort is a physiological cortisol replacement therapy. Chronocort is a modified release formulation that delivers hydrocortisone in a manner that mimics the body's normal circadian rhythm (the body's natural 24 hour hormone cycle). It was also under development for the treatment of hypopituitarism.
Diurnal Group overview
Diurnal Group is clinical stage pharmaceutical company that targets patient needs in chronic endocrine (hormonal) diseases. Its pipeline products include DNL-0200, DNL-0300, DNL-0400 and DNL-0500. The company offers treatment for congenital adrenal hyperplasia (CAH), adrenal insufficiency, hypogonadism and hypothyroidism. It offers various products which include thyroxine (T4) tablets, hydrocortisone tablets, and fludrocortisone tablets. Diurnal Group is headquartered in Cardiff, Wales, the UK.
For a complete picture of Hydrocortisone MR’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
